Benzinga

Merck’s Pneumococcal Vaccine Lands FDA Nod, Just Few Weeks After Its Rival

For the second time in five weeks, the FDA has approved a new pneumococcal conjugate vaccine, this time giving the nod to a shot from Merck & Co Inc (NYSE: MRK). The vaccine, Vaxneuvance, is designed to protect against 15 strains of pneumococcal bacteria. That’s two more strains than Prevnar 13, a product from rival Pfizer Inc (NYSE: PFE). But the total number of strains covered by Vaxneuvance is five shy of Prevnar 13’s successor, Prevnar 20, which the FDA approved in June. The clinical studies

LEAVE A REPLY

Please enter your comment!
Please enter your name here